^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    simridarlimab (IBI-322)

    i
    Other names: IBI-322, IBI322, IBI 322
    Associations

    News

    Trials
    Company:
    Innovent Biologics
    Drug class:
    PD-L1 inhibitor, CD47 inhibitor
    Related drugs:
    Associations

    News

    Trials
    15d
    A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Hematologic Malignancy (clinicaltrials.gov)
    P1, N=70, Completed, Innovent Biologics (Suzhou) Co. Ltd. | Recruiting --> Completed | N=230 --> 70
    Trial completion • Enrollment change
    |
    simridarlimab (IBI-322)
    1year
    Safety and Efficacy of IBI322 in Chinese Subjects With Advanced Malignant Tumors (clinicaltrials.gov)
    P1a/1b, N=94, Completed, Innovent Biologics (Suzhou) Co. Ltd. | Active, not recruiting --> Completed | N=218 --> 94 | Trial completion date: Dec 2023 --> Aug 2023
    Trial completion • Enrollment change • Trial completion date • Metastases
    |
    simridarlimab (IBI-322)
    1year
    A Phase 1a Study Evaluating the Safety, Tolerability, and Efficacy of IBI322 in Subjects With Advanced Cancers (clinicaltrials.gov)
    P1a, N=22, Completed, Innovent Biologics (Suzhou) Co. Ltd. | Recruiting --> Completed | N=51 --> 22 | Trial completion date: Jul 2023 --> Feb 2023
    Trial completion • Enrollment change • Trial completion date • Metastases
    |
    simridarlimab (IBI-322)
    1year
    A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Myeloid Tumor (clinicaltrials.gov)
    P1a/1b, N=1, Terminated, Innovent Biologics (Suzhou) Co. Ltd. | N=124 --> 1 | Trial completion date: May 2024 --> Aug 2023 | Not yet recruiting --> Terminated; Due to the company's development strategy adjustment]
    Enrollment change • Trial completion date • Trial termination
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    simridarlimab (IBI-322)
    over1year
    CD47/PD-L1 BISPECIFIC ANTIBODY (IBI322) IN ANTI-PD-1 OR PD-L1 TREATMENT-RESISTANT CLASSICAL HODGKIN LYMPHOMA: A PHASE I STUDY (EHA 2023)
    Despite the excellent efficacy of PD-1 or PD-L1 inhibitors and brentuximab vedotin (BV) in relapsed or refractory classical Hodgkin lymphoma (cHL), some patients (pts) still have disease progression. IBI322 monotherapy showed a promising anti-tumor effectivity with a manageable safety profile in anti-PD-1 or PD-L1 treatment-resistant classical Hodgkin Lymphoma patients. Clinical trial information: NCT04795128 Hodgkin's lymphoma, Resistance, Immune therapy
    P1 data
    |
    SIRPA (Signal Regulatory Protein Alpha)
    |
    Adcetris (brentuximab vedotin) • simridarlimab (IBI-322)
    over1year
    Efficacy and Biomarker Explanation of IBI-322 +Lenvatinib Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, Hunan Province Tumor Hospital | Initiation date: Jul 2022 --> Mar 2023 | Trial primary completion date: Apr 2023 --> Dec 2023
    Trial initiation date • Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK rearrangement
    |
    Alecensa (alectinib) • Lenvima (lenvatinib) • simridarlimab (IBI-322)
    over2years
    Efficacy and Biomarker Explanation of IBI-322 +Lenvatinib Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, Hunan Province Tumor Hospital
    New P2 trial
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK rearrangement
    |
    Alecensa (alectinib) • Lenvima (lenvatinib) • simridarlimab (IBI-322)